Prosecution Insights
Last updated: April 19, 2026
Application No. 18/549,412

METHOD FOR PREPARING AMIDINES

Non-Final OA §102§103§112§DP
Filed
Sep 07, 2023
Examiner
MCANANY, JOHN D
Art Unit
1625
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
VERSALIS S.P.A.
OA Round
1 (Non-Final)
67%
Grant Probability
Favorable
1-2
OA Rounds
3y 2m
To Grant
99%
With Interview

Examiner Intelligence

Grants 67% — above average
67%
Career Allow Rate
33 granted / 49 resolved
+7.3% vs TC avg
Strong +51% interview lift
Without
With
+51.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 2m
Avg Prosecution
39 currently pending
Career history
88
Total Applications
across all art units

Statute-Specific Performance

§101
0.7%
-39.3% vs TC avg
§103
30.6%
-9.4% vs TC avg
§102
21.8%
-18.2% vs TC avg
§112
30.3%
-9.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 49 resolved cases

Office Action

§102 §103 §112 §DP
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. Current Status of 18/549,412 This Office Action is responsive to the amended claims received 7 September 2023. Claims 1-11 are currently pending. Priority Applicant’s claim for the benefit of the prior-filed applications PCT/IB2022/051866 (filed 3 March 2022) and IT 102021000005336 (filed 8 March 2021) under 35 U.S.C. 119(e), 120, 121, 365(c), or 386(c) is acknowledged. Receipt is acknowledged of certified copies of papers required by 37 CFR 1.55. The Examiner has determined, for the purposes of the instant action, that the effective filing date of the instant claims is 3 March 2022, at least due to the lack of an English translation of the earlier priority document. Should applicant desire to obtain the benefit of foreign priority under 35 U.S.C. 119(a)-(d) prior to declaration of an interference, a certified English translation of the foreign application must be submitted in reply to this action. 37 CFR 41.154(b) and 41.202(e). Information Disclosure Statement The information disclosure statements (IDS) received on 7 September 2023, 24 October 2023, 6 August 2025, and 13 January 2026 are in compliance with the provisions of 37 CFR 1.97. Accordingly, these information disclosure statements are being considered by the Examiner. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-2, 5, and 9-10 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 1 recites limitations that include either the phrase “preferably” or the phrase “more preferably” multiple times. Exemplary and/or preferential claim limitations cause the reader to be confused as to the exact scope of a claim. See MPEP 2173.05(c)(I) and MPEP 2173.05(d). These limitations render claim 1 indefinite. Applicant may choose to delete all preferential limitations from claim 1. Claim 2 recites the limitation “(SiO2-Al2O3)”, wherein that second “2” is not superscript nor subscript. The meaning of that “2” is not clear. This renders claim 2 indefinite. Applicant may choose to amend that “2” to be subscript”. Claim 2 recites the phrase “aluminum oxide (γ-Al2O3)”. It is the Examiner’s opinion that the chemical formula within the parentheses therein is not identical in scope to the phrase within parentheses. For example, aluminum oxide may also be made up of α-Al2O3. It is not clear if the phrase within parentheses is an exemplary or required limitation of the claim. This renders claim 2 indefinite. Applicant may replace the phrase “aluminum oxide (γ-Al2O3) and silico-aluminas (SiO2-Al2O3)” with the phrase “aluminum oxide, γ-Al2O3, and silico-aluminas (SiO2-Al2O3)”. Claim 5 recites the phrase “supported/bound on”. The exact meaning of this term is unclear, and renders claim 5 indefinite. Applicant may choose to replace the quoted term with “supported by or bound onto”. Claim 9 recites “relative to the entire reagent mixture” within parentheses. It is unclear if this phrase is an exemplary or required limitation of the claim. This renders claims 9-10 indefinite. Applicant may choose to move the quoted phrase above out of the parentheses. Claim 10 recites “a pressure comprised between 0.08 and 5 BarA”. The meaning of “comprised” within this phrase is unclear, and renders claim 10 indefinite. Applicant may choose to delete the word “comprised” in the quoted phrase. The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph: Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claim 4 is rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Claim 4 recites the limitation “or ion exchange resins”. Not all ion exchange resins fall within the scope of the “heterogeneous acid catalysts based on acid resins” (some are basic) defined within instant claim 1. Therefore, claim 4 attempts to expand its scope beyond that of instant claim 1. Applicant may choose to replace the phrase “or ion exchange resins” within claim 4 with the following “or acidic ion exchange resins”. Applicant may cancel the claim, amend the claim to place the claim in proper dependent form, rewrite the claim in independent form, or present a sufficient showing that the dependent claim complies with the statutory requirements. Claim Interpretation The Examiner is interpreting the unit “BarA” within claim 10 to indicate absolute pressure in bar. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claims 1, 6, and 11 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by: MA (CN 1546492A, Publication Date 17 November 2004, Cited by Applicant in IDS of 7 September 2023, the Examiner included a copy with a machine translation herein) as evidenced by: AMARASEKARA (Amarasekara, A.S.; Ha, U.; Okorie, N.C. “Renewable Polymers: Synthesis and Characterization of Poly(levulinic acid–pentaerythritol)” JOURNAL OF POLYMER SCIENCE, PART A: POLYMER CHEMISTRY 2018, 56, 955–958). MA teaches, at the bottom of claim 1, that the cycloaddition reaction is performed by combining aminopropyl caprolactam (drawn below) with antimony trioxide. PNG media_image1.png 180 266 media_image1.png Greyscale MA teaches that the reaction is maintained at 150-160 °C for 20-30 hours until the reaction “no longer produces water” (claim 1 of MA). MA teaches that this reaction yields 1,8-diazabicyclo(5,4,0)-7-undecene (DBU) (claim 1 of MA). Example 1 of MA gives additional details for the same reaction. MA teaches that a reflux condenser and a “water separator” are added to four-neck flask wherein the reaction is performed (example 1). MA teaches that the reaction is performed at 155 °C for 20 hours (example 1). One of ordinary skill in the art would understand the “water separator” referred to by MA to be a Dean-Stark trap. AMARASEKARA provides evidence that antimony trioxide (Sb2O3) is a Lewis acid. AMARASEKARA refers to Sb2O3 as a Lewis acid catalyst in the first paragraph of page 956 therein. Regarding claim 6: The teachings of claim 1 of MA do not mention a solvent being present within the DBU formation reaction. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 1, 6, and 8-11 are rejected under 35 U.S.C. 103 as being unpatentable over: MA (CN 1546492A, Publication Date 17 November 2004, Cited by Applicant in IDS of 7 September 2023, the Examiner included a copy with a machine translation herein) in view of: XU (WO 2019/000069 A1; International Publication Date 3 January 2019) as evidenced by: AMARASEKARA (Amarasekara, A.S.; Ha, U.; Okorie, N.C. “Renewable Polymers: Synthesis and Characterization of Poly(levulinic acid–pentaerythritol)” JOURNAL OF POLYMER SCIENCE, PART A: POLYMER CHEMISTRY 2018, 56, 955–958). Regarding claims 8: Teachings of MA and evidence provided by AMARASEKARA are discussed above. Neither MA nor AMARASEKARA mention tubular reactors. XU teaches the use of a continuous-flow tubular reactor to perform a catalyzed chemical reaction (abstract). XU teaches that continuous tubular reactors allow for large-scale production of materials (Pg. 45, Ln. 6-7). Page 27 of XU teaches that the “weight hourly space velocity” (WHSV) was used as “an indicator of the reactant retention/residence time within the catalyst bed”, and XU teaches how this value is calculated. Continuous tubular reactors are a known tool within the chemical arts that allow chemical reactions to be scaled up. One of ordinary skill in the art would have been familiar with this tool, as taught by XU. It would have been obvious to one of ordinary skill in the art, before the instant effective filing date, to perform the reaction described by MA within a continuous tubular reactor system (as taught by XU), for the purpose of producing a larger amount of the product DBU. The artisan would have expected success in this combination, because the reaction chemistry was known from MA, and scaling up a reaction using a continuous tubular reactor was a common practice in the art. Regarding claims 9: It would have been obvious to one of ordinary skill in the art to alter the parameters of the reaction, such as the mass of the catalyst and the feed rate of the starting material to achieve optimum yields with reduced side products. Regarding claims 10: It would have been obvious to one of ordinary skill in the art to perform the reaction of MA at standard atmospheric pressure of about 1 bar. Claims 1, 6-7, and 11 are rejected under 35 U.S.C. 103 as being unpatentable over: MA (CN 1546492A, Publication Date 17 November 2004, Cited by Applicant in IDS of 7 September 2023, the Examiner included a copy with a machine translation herein) in view of: OSTROWSKA (N-Alkyl-, N-Aryl-, and N-Hetaryl-Substituted Amidines (Imidamides), Ostrowska, K., Kolasa, A., Science of Synthesis, (2005) 22, 379. DOI: 10.1055/sos-SD-022-00489) as evidenced by: AMARASEKARA (Amarasekara, A.S.; Ha, U.; Okorie, N.C. “Renewable Polymers: Synthesis and Characterization of Poly(levulinic acid–pentaerythritol)” JOURNAL OF POLYMER SCIENCE, PART A: POLYMER CHEMISTRY 2018, 56, 955–958). Regarding claim 7: Teachings of MA and evidence provided by AMARASEKARA are discussed above. The teachings of MA do not specify any solvent to be present during the intramolecular reductive amination discussed above. OSTROWSKA teaches the synthesis of 1,5-diazabicyclo(4.3.0)non-5-ene, which is a compound very similar to DBU, on page 434 therein, as shown below. PNG media_image2.png 163 621 media_image2.png Greyscale OSTROWSKA teaches the reaction conditions for this exemplary reaction to be refluxing for 12 hours in xylene, with 4-toluenesulfonic acid being present. OSTROWSKA teaches that these reactions are typically performed while simultaneously removing water from the reaction (page 434). It would have been obvious to one of ordinary skill in the art, before the instant effective filing date, to add the antimony trioxide catalyst taught by MA into the 1,5-diazabicyclo(4.3.0)non-5-ene synthesis reaction taught by OSTROWSKA, for the purpose of increasing the total yield of the reaction. The artisan would have expected success in this combination, because antimony trioxide is taught by MA to catalyze a reaction that is nearly identical to that of OSTROWSKA. Claims 1-3, 6, and 11 are rejected under 35 U.S.C. 103 as being unpatentable over: MA (CN 1546492A, Publication Date 17 November 2004, Cited by Applicant in IDS of 7 September 2023, the Examiner included a copy with a machine translation herein) in view of: BADLANI (Badlani, M.; Wachs, I.E. “Methanol: a ‘smart’ chemical probe molecule” Catalysis Letters Vol. 75, No. 3–4, 2001) as evidenced by: AMARASEKARA (Amarasekara, A.S.; Ha, U.; Okorie, N.C. “Renewable Polymers: Synthesis and Characterization of Poly(levulinic acid–pentaerythritol)” JOURNAL OF POLYMER SCIENCE, PART A: POLYMER CHEMISTRY 2018, 56, 955–958). Regarding claims 2-3: Teachings of MA and evidence provided by AMARASEKARA are discussed above. Neither MA nor AMARASEKARA discuss metal oxide catalysts other than antimony trioxide. BALDANI generally teaches a method of determining the concentration of active sites on one-component metal oxide catalysts (abstract). BALDANI also reports on the relative ability of these metal catalysts to oxidize methanol (Pg. 146). The list of metal oxide catalysts taught by BALDANI includes 38 metal oxides, and specifically includes Sb2O3, Al2O3, and La2O3 (abstract). One of ordinary skill in the art, reading the teachings of MA would wonder if any other catalysts would work for the final DBU synthesis reaction. Specifically, one of ordinary skill in the art would logically think that other metal oxides may be tested to optimize the yield and minimize unwanted products in that reaction. The artisan would have come across lists of metal oxides useful for catalyzing chemical reactions, such as the list taught by BALDANI. It would have been obvious to one of ordinary skill in the art, before the instant effective filing date, to test all of metal oxide catalysts taught by BALDANI within the reaction taught by MA, for the purpose of optimizing the yield and minimizing unwanted products in that reaction. The artisan would have expected success in this trial, because all of the metal oxides within BALDANI are taught to be catalysts. Claims 1, 4-5, and 7 are rejected under 35 U.S.C. 103 as being unpatentable over: OSTROWSKA (N-Alkyl-, N-Aryl-, and N-Hetaryl-Substituted Amidines (Imidamides), Ostrowska, K., Kolasa, A., Science of Synthesis, (2005) 22, 379. DOI: 10.1055/sos-SD-022-00489) and in view of: HARMER 2001 (Harmer, M.A.; Sun, Q. “Solid acid catalysis using ion-exchange resins” Applied Catalysis A: General 221 (2001) 45–62). Teachings of OSTROWSKA are discussed above. OSTROWSKA teaches the synthesis of 1,5-diazabicyclo(4.3.0)non-5-ene, which is a compound very similar to DBU, on page 434 therein, as shown below. PNG media_image2.png 163 621 media_image2.png Greyscale OSTROWSKA teaches the reaction conditions for this exemplary reaction to be refluxing for 12 hours in xylene, with 4-toluenesulfonic acid being present. Xylenes are known to boil at about 140 °C. OSTROWSKA teaches that these reactions are typically performed while simultaneously removing water from the reaction (page 434). OSTROWSKA does not teach “an acid catalyst” as defined at the bottom of instant claim 1. HARMER teaches the use of ion-exchange resins, specifically styrene-supported sulfonic acids, as catalysts within various organic reactions (abstract). HARMER teaches that homogeneous catalysts, such as sulfuric acid, can be replaced by heterogeneous resin-based catalysts (Pg. 56, 2nd paragraph). HARMER states that one of the benefits to using a solid (heterogeneous) catalyst is easy isolation of the product (introduction section and Pg. 59, 4th paragraph). A structure of the sulfonated polystyrene resin is provided in Fig. 1 of HARMER. One of ordinary skill in the art would have seen the reaction taught by OSTROWSKA, and would have been aware that using heterogeneous catalysts, specifically resin-based catalysts, is a known strategy within the chemical arts that allows for easy isolation of a product from a reaction mixture (as is taught by HARMER). It would have been obvious to one of ordinary skill in the art, before the instant effective filing date, to replace the solution-phase acid catalyst taught by OSTROWSKA (4-toluenesulfonic acid) with the heterogeneous resin-based version of the same acid taught by HARMER, for the purpose of increasing the ease of isolating the product from the reaction of OSTROWSKA. The artisan would have expected success in this replacement, because HARMER teaches the benefits of this type of catalyst replacement. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1-8 and 10-11 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over: Claims 1, 3, 9, 11, and 13 of copending Application No. 18/549,406 (referred to below as the ‘406 application). Although the claims at issue are not identical, they are not patentably distinct from each other because: Claim 1 of the ‘406 application teaches the synthesis of a compound of formula (V) from a compound of formula (IV), wherein these formulae are identical to those of the same designation in instant claim 1. Claim 1 of the ‘406 application also teaches that the reaction of formula (IV) is performed with dehydration in the presence of an acid catalyst. Claim 9 of the ‘406 application specifies the acid catalyst of claim 1 to be “a cobalt or nickel-based catalyst supported/bound on a Lewis acid or a Lewis acid having Bronsted acid components, preferably selected from Al2O3 and SiO2”. Together, claims 1 and 9 of the ‘406 application anticipate instant claims 1 and 2. Claim 3 of the ‘406 application anticipates instant claim 11, due to the compound of formula (V) being specified as DBU. Claim 11 of the ‘406 application teaches a continuously stirred tank reactor, which anticipates instant claim 8. Claim 13 of the ‘406 application teaches many specific reaction details that anticipate instant claims 3-7 and 10. This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. Claims 1, 3, and 5-11 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over: Claims 1 and 3-9 of copending Application No. 19-108,987 (referred to below as the ‘987 application). Although the claims at issue are not identical, they are not patentably distinct from each other because: Claim 1 of the ‘987 application teaches the synthesis of a compound of formula (V) from a compound of formula (IV), wherein these formulae are identical to those of the same designation in instant claim 1. Claim 1 of the ‘987 application also teaches that the reaction of formula (IV) is performed with dehydration in the presence of zirconium oxide. Claim 1 of the ‘987 application anticipates instant claims 1 and 3. Claims 3, 4, 5, 6, 7, 8, and 9 of the ‘987 application anticipate instant claims 5, 6, 7, 8, 9, 10, and 11 respectively. This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. Conclusion No claims are currently allowable. Any inquiry concerning this communication or earlier communications from the examiner should be directed to JOHN D MCANANY whose telephone number is (571)270-0850. The examiner can normally be reached 8:30 AM - 5:30 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, ANDREW D KOSAR can be reached at (571)272-0913. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JDMc/Examiner, Art Unit 1625 /Andrew D Kosar/Supervisory Patent Examiner, Art Unit 1625
Read full office action

Prosecution Timeline

Sep 07, 2023
Application Filed
Feb 12, 2026
Non-Final Rejection — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12583853
1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC AND AUTOIMMUNE DISEASES
2y 5m to grant Granted Mar 24, 2026
Patent 12559497
IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS
2y 5m to grant Granted Feb 24, 2026
Patent 12552768
PYRIDINYLPYRAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND USE THEREOF
2y 5m to grant Granted Feb 17, 2026
Patent 12545682
Heterocyclic Derivatives as P2X7 Receptor Antagonists
2y 5m to grant Granted Feb 10, 2026
Patent 12535735
Modified Thioxanthone Photoinitiators
2y 5m to grant Granted Jan 27, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
67%
Grant Probability
99%
With Interview (+51.0%)
3y 2m
Median Time to Grant
Low
PTA Risk
Based on 49 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month